Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is prescribed to lower intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension.\n\nGNH India supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iricryn is a prostaglandin analog used to manage conditions that require reduction of intra‑ocular pressure.\n\nPrimary open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression.\nOcular hypertension: reduces pressure to prevent conversion to glaucoma.\nGlaucoma (any type): helps control intra‑ocular pressure across various glaucoma diagnoses.

Bimatoprost may cause ocular and systemic reactions.\n\nCommon Side Effects:\n- Eye redness (hyperemia)\n- Increased eyelash growth\n- Eye irritation or foreign‑body sensation\n- Blurred vision\n- Darkening of the iris or peri‑ocular skin\n- Mild eye discomfort\n\nSerious or Rare Side Effects:\n- Severe eye inflammation (uveitis)\n- Allergic reactions with swelling or rash\n- Paradoxical increase in intra‑ocular pressure\n- Corneal edema or clouding\n- Ocular infection\n- Vision loss or significant visual disturbance

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.\n\nMonitor intra‑ocular pressure regularly: ensure therapeutic effect and detect paradoxical rise.\nAssess for ocular infections or inflammation: avoid use in active infection.\nAvoid use in patients with active ocular inflammation: may exacerbate condition.\nUse caution during pregnancy and breastfeeding: safety data are limited.\nDiscontinue and seek medical advice if severe side effects occur.\nStore at room temperature: keep bottle tightly closed, protect from light and moisture.

Bimatoprost can interact with other ocular medications and systemic agents.\n\nMajor Interactions (Avoid):\n- Concurrent use with other prostaglandin analog eye drops: may increase risk of ocular irritation.\n- Use with topical corticosteroids: can reduce efficacy of pressure‑lowering effect.\n\nModerate Interactions (Monitor Closely):\n- Combination with beta‑blocker eye drops: monitor for additive IOP‑lowering effect.\n- Systemic carbonic anhydrase inhibitors: may enhance overall pressure reduction.\n- Anticholinergic agents: observe for potential changes in pupil size.